Clinical Trial Update: TOL-463 Phase 2 Study for Vaginitis [Phase 2]

View source ↗

Summary

The Phase 2 study of TOL-463 for vaginitis, covering bacterial vaginosis and vulvovaginal candidiasis, has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bacterial Vaginosis
• Vulvovaginal Candidiasis

Drugs mentioned

• TOL-463

Snippet

Sponsor: Toltec Pharmaceuticals, LLC | Conditions: Bacterial Vaginosis, Vulvovaginal Candidiasis | Phase 2 | Status: COMPLETED